Skip to main content

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Completed · Phase 3 · NCT03238326

Conditions: Schizophrenia

At a glance

Research payments reported, 2025
$32,834
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
295

About the trial

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (with H. Lundbeck A/S)
Tested
Brexpiprazole (drug)
Dates
Started 2017-08-23; completion 2025-04-22
Results posted
Yes

To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia

From ClinicalTrials.gov, last updated 2026-02-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Otsuka Pharmaceutical Development & Commercialization, Inc. reported $32,834 in research payments for this study in 2025 (13 payments).

Products named: Rexulti

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • $8,557
  • Atlanta Center for Medical Research LLC $6,746
  • Punitha Rathnam New Dawn Psychiatric Services PLLC $6,621
  • Erg Clinical Research New York PLLC $2,676
  • Lake Charles Clinical Trials LLC $2,000
  • North Texas Psychiatric Association PA $1,955
  • Cutting Edge Research Group $1,805
  • Rakesh Ranjan MD & Associates Inc $1,000
  • Proscienceresearchgroup LLC $1,000
  • Harmonex Inc $399
  • Central States Research LLC $75

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.